Hypertension in Cancer Patients Treated with Anti-angiogenic Based Regimens

Overview

Journal Cardiooncology

Publisher Biomed Central

Specialty Oncology

Date 2021 Feb 3

PMID 33530150

Citations 18

Authors

Yishay Wasserstrum

Ran Kornowski

Pia Raanani

Avi Leader

Oren Pasvolsky

Zaza Iakobishvili

Affiliations

Soon will be listed here.

Abstract

New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors.

Citing Articles

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice.

Capdevila J, Deandreis D, Durante C, Leboulleux S, Luster M, Netea-Maier R Eur Thyroid J. 2023; 12(5).

PMID: 37429326 PMC: 10448584. DOI: 10.1530/ETJ-23-0068.

Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.

Lee N, Lee J, Lee J Target Oncol. 2023; 18(2):247-255.

PMID: 36826462 DOI: 10.1007/s11523-023-00951-z.

Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory-differentiated thyroid cancer.

Jimenez-Fonseca P Cancer Med. 2022; 11 Suppl 1:17-25.

PMID: 36202605 PMC: 9537056. DOI: 10.1002/cam4.5127.

Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity.

Scott S, Greenlee A, Matzko A, Stein M, Naughton M, Zaramo T Heart Fail Clin. 2022; 18(3):425-442.

PMID: 35718417 PMC: 10391230. DOI: 10.1016/j.hfc.2022.02.003.

Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors.

Hong S, Daniels B, van Leeuwen M, Pearson S, Vajdic C Discov Oncol. 2022; 13(1):6.

PMID: 35201530 PMC: 8777550. DOI: 10.1007/s12672-022-00468-3.

References

Zou A, Cowley Jr A . Role of nitric oxide in the control of renal function and salt sensitivity. Curr Hypertens Rep. 2000; 1(2):178-86. DOI: 10.1007/s11906-999-0016-7. View

Campbell N, Kunnavakkam R, Leighl N, Vincent M, Gandara D, Koczywas M . Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012; 78(1):76-80. PMC: 4319647. DOI: 10.1016/j.lungcan.2012.06.011. View

McNamara M, Le L, Horgan A, Aspinall A, Burak K, Dhani N . A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer. 2015; 121(10):1620-7. DOI: 10.1002/cncr.29227. View

Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P . Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU Int. 2014; 117(1):110-7. DOI: 10.1111/bju.12940. View

Hu-Lowe D, Zou H, Grazzini M, Hallin M, Wickman G, Amundson K . Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008; 14(22):7272-83. DOI: 10.1158/1078-0432.CCR-08-0652. View

Smith D, Smith M, Sweeney C, Elfiky A, Logothetis C, Corn P . Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2012; 31(4):412-9. PMC: 4110249. DOI: 10.1200/JCO.2012.45.0494. View

Spano J, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C . Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008; 371(9630):2101-8. DOI: 10.1016/S0140-6736(08)60661-3. View

Khoja L, Kumaran G, Zee Y, Murukesh N, Swindell R, Saunders M . Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. J Clin Gastroenterol. 2013; 48(5):430-4. DOI: 10.1097/MCG.0b013e3182a8804c. View

Motzer R, Escudier B, Tomczak P, Hutson T, Michaelson M, Negrier S . Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14(6):552-62. DOI: 10.1016/S1470-2045(13)70093-7. View

10.

Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E . Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer. 2012; 48(4):527-37. DOI: 10.1016/j.ejca.2011.12.022. View

11.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

12.

Rini B, Quinn D, Baum M, Wood L, Tarazi J, Rosbrook B . Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol. 2014; 10(1):45-53. PMC: 4363524. DOI: 10.1007/s11523-014-0307-z. View

13.

Thulliez M, Angoulvant D, Le Lez M, Jonville-Bera A, Pisella P, Gueyffier F . Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014; 132(11):1317-26. DOI: 10.1001/jamaophthalmol.2014.2333. View

14.

Campos S, Penson R, Matulonis U, Horowitz N, Whalen C, Pereira L . A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2012; 128(2):215-20. DOI: 10.1016/j.ygyno.2012.07.126. View

15.

Kindler H, Ioka T, Richel D, Bennouna J, Letourneau R, Okusaka T . Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011; 12(3):256-62. DOI: 10.1016/S1470-2045(11)70004-3. View

16.

Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28):2159-219. DOI: 10.1093/eurheartj/eht151. View

17.

Scotland R, Madhani M, Chauhan S, Moncada S, Andresen J, Nilsson H . Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation. 2005; 111(6):796-803. DOI: 10.1161/01.CIR.0000155238.70797.4E. View

18.

Sternberg C, Davis I, Mardiak J, Szczylik C, Lee E, Wagstaff J . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6):1061-8. DOI: 10.1200/JCO.2009.23.9764. View

19.

Hyams D, Chan A, de Oliveira C, Snyder R, Vinholes J, Audeh M . Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Invest New Drugs. 2013; 31(5):1345-54. DOI: 10.1007/s10637-013-9991-2. View

20.

Steingart R, Yadav N, Manrique C, Carver J, Liu J . Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. Semin Oncol. 2013; 40(6):690-708. DOI: 10.1053/j.seminoncol.2013.09.010. View